RH and Adolescents

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

77 participants

Study Classification

OBSERVATIONAL

Study Start Date

2013-03-31

Study Completion Date

2015-11-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study will create a model of reproductive health services for HIV-positive female adolescents in Asia.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Very Early Intensive Treatment of Infants Living With HIV to Achieve HIV Remission

NCT02140255

HIV Infection

RECRUITING PHASE1/PHASE2

Contraceptive/HIV Affecting Risk in Adolescents

NCT03301480

Contraception Hiv

TERMINATED

A Prospective Cohort of Children With HIV Infection

NCT00476606

HIV Infections

COMPLETED

Hormonal Birth Control and the Risk of Acquiring HIV

NCT00006324

HIV Infections

COMPLETED NA

Cohort of Young Adults Infected With HIV Since Birth or During Childhood

NCT01269632

HIV Infection Young Adult

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

For the implementation of risk reduction interventions, it is equally important to provide specific knowledge and continuous counseling on different preventive options. A perfect preventive method, which provides highly reliable dual protection both from unintended pregnancies and from HIV/STDs with no side effects and which is completely accepted, is not available. Many authors consider that the most effective way to achieve dual protection is the simultaneous use of two contraceptive methods, one of which is a barrier method such as the male or female condom, and the other a highly effective contraceptive method, such as hormonal contraception (HC), intrauterine device (IUD) or sterilization. This is called dual contraception. Therefore this project will focus on specific reproductive service delivery for these groups of patients. As the age group is very young, the investigators will use in the study only reversible highly effective methods of contraception - HC, combined or progestin only, and an IUD - and condoms. For example, HC for HIV-positive women has been studied extensively in the last two decades, yet there are still no definitive answers regarding key issues - HIV disease progression, genital tract HIV shedding and infectivity, pharmacokinetic (PK) interactions between hormones and ARVs, and therefore a possibility for compromise of contraceptive effect and/or ARV failure, and last but not least, metabolic outcomes. Data on the effect of hormonal contraception on HIV disease progression is still inconclusive. Unfortunately there is only a limited number of studies in this field, with very small sample sizes and in most cases outside "real life" conditions.

There are three substudies:

1. Pharmacokinetic interactions between the sex steroid hormones and the protease inhibitors in HIV-positive Thai female adolescents
2. Assessment of premenstrual syndrome in HIV-positive adolescents
3. Metabolic changes in HIV + female adolescents on ART with hormonal contraception

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Reproductive Health

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

HIV female adolescents

sexually active, HIV-infected female adolescents, 12-24 years old who are aware of their HIV status

reversible contraceptive methods

Intervention Type OTHER

1. Consistent male condom use only
2. Consistent female condom use only
3. Hormonal contraception, combined oral contraceptive pills and male/female condom
4. Hormonal contraception, progestin only depot medroxyprogesterone acetate (DMPA) injectable and male/female condom
5. Hormonal contraception , progestin only hormonal implant and male/female condom
6. Intrauterine device and male/female condom

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

reversible contraceptive methods

1. Consistent male condom use only
2. Consistent female condom use only
3. Hormonal contraception, combined oral contraceptive pills and male/female condom
4. Hormonal contraception, progestin only depot medroxyprogesterone acetate (DMPA) injectable and male/female condom
5. Hormonal contraception , progestin only hormonal implant and male/female condom
6. Intrauterine device and male/female condom

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Female 12 to 24 years of age
* HIV-positive status
* HIV-disclosed before screening visit
* Having had first menstrual cycle (menarche)
* Sexually active
* Willing to participate in the study and signed informed consent form, including signed inform consent by caretaker for subjects \<18 years of age

Exclusion Criteria

* Being pregnant at the time of screening visit
* Mental or physical conditions that may limit informed participation in the study
* Having active AIDS or opportunistic infections

Non-eligible subjects to use hormonal contraception:

* Thrombosis or history of it
* Family history of thrombosis
* Hypertension (for combined oral contraceptives)
* Hyperlipidemia (toxicity grade \>3)
* Diabetes mellitus with vascular involvement
* Presence or history of liver hepatic disease
* Malignant disease of genital organs and breast
* Undiagnosed vaginal bleeding
* Lactation
* Hypersensitivity to steroid hormones

Eligible subjects to use intrauterine device:

* In case of HAART, last CD4 count \> 200 cells/mm3 no more than 6 months prior to the screening
* If without HAART, last CD4 count \>350 cells/mm3 no more than 6 months prior to the screening
* Normal cervical Pap smear in the last 6 months/in the day of IUD insertion

Non-eligible subjects to use intrauterine device:

* Having an active infection of the vagina or cervix
* Having pelvic inflammatory disease (PID) or have a recent history of PID
* Having a bleeding disorder or taking anticoagulants
* Having abnormalities of the uterus
* Having a uterine infection after childbirth or a septic abortion
* Having uterine bleeding of unknown origin
* Having an allergy to copper

Minimum Eligible Age

12 Years

Maximum Eligible Age

24 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

No